Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Pacira BioSciences, Inc. (NASDAQ: PCRX)
PCRX Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-7.40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
44.30%
PCRX Stock Analysis
PCRX
PE Ratio:
186
PCRX
PEG Ratio:
7.3
PCRX
Forward EPS Growth (12 month):
25.50%
PCRX
PS Ratio:
1.2
PCRX
PSG Ratio:
0.2
PCRX
Forward Revenue Growth (12 month):
7.90%
PCRX Articles
No data was found